Iproclozide

Revision as of 16:32, 20 August 2015 by WikiBot (talk | contribs) (Protected "Iproclozide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Iproclozide
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H15ClN2O2
Molar mass242.70 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Iproclozide

Articles

Most recent articles on Iproclozide

Most cited articles on Iproclozide

Review articles on Iproclozide

Articles on Iproclozide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Iproclozide

Images of Iproclozide

Photos of Iproclozide

Podcasts & MP3s on Iproclozide

Videos on Iproclozide

Evidence Based Medicine

Cochrane Collaboration on Iproclozide

Bandolier on Iproclozide

TRIP on Iproclozide

Clinical Trials

Ongoing Trials on Iproclozide at Clinical Trials.gov

Trial results on Iproclozide

Clinical Trials on Iproclozide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Iproclozide

NICE Guidance on Iproclozide

NHS PRODIGY Guidance

FDA on Iproclozide

CDC on Iproclozide

Books

Books on Iproclozide

News

Iproclozide in the news

Be alerted to news on Iproclozide

News trends on Iproclozide

Commentary

Blogs on Iproclozide

Definitions

Definitions of Iproclozide

Patient Resources / Community

Patient resources on Iproclozide

Discussion groups on Iproclozide

Patient Handouts on Iproclozide

Directions to Hospitals Treating Iproclozide

Risk calculators and risk factors for Iproclozide

Healthcare Provider Resources

Symptoms of Iproclozide

Causes & Risk Factors for Iproclozide

Diagnostic studies for Iproclozide

Treatment of Iproclozide

Continuing Medical Education (CME)

CME Programs on Iproclozide

International

Iproclozide en Espanol

Iproclozide en Francais

Business

Iproclozide in the Marketplace

Patents on Iproclozide

Experimental / Informatics

List of terms related to Iproclozide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[1] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[2][3]

See also

References

  1. Suerinck A, Suerinck E. (1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de médecine de Lyon. 47 (96): 573–586. PMID 5930723.
  2. Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP. (1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. PMID 680506.
  3. Neil Kaplowitz, Laurie D. DeLeve (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3. ISBN 9780824708115.

Template:Antidepressants Template:Anxiolytics